CoChat
Sign Up
Cited by 163

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Gastric Inhibitory Polypeptide and Glucagon-Like Peptide-1 in the Pathogenesis of Type 2 Diabetes

Nauck, Michael A., Baller, Birgit, Meier, Juris J.·2004·Diabetes
DOI 10.2337/diabetes.53.suppl_3.s190
Open this paper in CoChat — free account

Abstract

The incretin effect denominates the phenomenon that oral glucose elicits a higher insulin response than does intravenous glucose. The two hormones responsible for the incretin effect, glucose-dependent insulinotropic hormone (GIP) and glucagon-like peptide-1 (GLP-1), are secreted after oral glucose loads and augment insulin secretion in response to hyperglycemia. In patients with type 2 diabetes, the incretin effect is reduced, and there is a moderate degree of GLP-1 hyposecretion. However, the insulinotropic response to GLP-1 is well maintained in type 2 diabetes. GIP is secreted normally or hypersecreted in type 2 diabetes; however, the responsiveness of the endocrine pancreas to GIP is greatly reduced. In ∼50% of first-degree relatives of patients with type 2 diabetes, similarly reduced insulinotropic responses toward exogenous GIP can be observed, without significantly changed secretion of GIP or GLP-1 after oral glucose. This opens the possibility that a reduced responsiveness to GIP is an early step in the pathogenesis of type 2 diabetes. On the other hand, this provides a basis to use incretin hormones, especially GLP-1 and its derivatives, to replace a deficiency in incretin-mediated insulin secretion in the treatment of type 2 diabetes.

Overview

Integrity signals

Registry

Crossref · 10.2337/diabetes.53.suppl_3.s190

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 14 references

Research works printed but not linked: 54

  1. Ørskov C, Rabenhøj L, Wettergren A, Kofod H, Holst JJ: Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide 1 in humans. Diabetes 43:535–539,1994 · DOI
  2. Deacon CF, Nauck MA, Meier J, Hücking K, Holst JJ: Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J Clin Endocrinol Metab 85:3575–3581,2000 · DOI
  3. Eaton RP, Allen RC, Schade DS, Erickson KM, Standefer J: Prehepatic insulin production in man: kinetic analysis using peripheral connecting peptide behaviour. J Clin Endocrinol Metab 51:520–528,1980 · DOI · Paper page
  4. Polonsky KS, Licinio-Paixao J, Given BD, Pugh W, Rue P, Galloway J, Karrison T, Frank B: Use of biosynthetic human C-peptide in the measurement of insulin secretion rates in normal volunteers and type 1 diabetic patients. J Clin Invest 77:98–105,1986 · DOI · Paper page
  5. Creutzfeldt W: The incretin concept today. Diabetologia 16:75–85,1979 · DOI · Paper page
  6. Holst JJ: Glucagonlike peptide 1: a newly discovered gastrointestinal hormone. Gastroenterology 107:1848–1855,1994 · DOI · Paper page
  7. Nauck MA: Glucagonlike peptide 1. Curr Opin Endocrinol Diabetes 4:256–261,1997 · DOI
  8. Nauck MA: Is glucagon-like peptide 1 an incretin hormone?Diabetologia 42:373–379,1999 · DOI
  9. Meier JJ, Nauck MA, Schmidt WE, Gallwitz B: Gastric inhibitory polypeptide: the neglected incretin revisited. Regul Pept 107:1–13,2002 · DOI
  10. Drucker DJ: Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology 122:531–544,2002 · DOI
  11. Nauck MA, Meier JJ, Creutzfeldt W: Incretins and their analogues as new antidiabetic drugs. Drug News Perspect 16:413–422,2003 · DOI
  12. Shuster LT, Go VLW, Rizza RA, O’Brien PC, Service FJ: Incretin effect due to increased secretion and decreased clearance of insulin in normal humans. Diabetes 37:200–203,1988 · DOI
  13. Gibby OM, Hales CN: Oral glucose decreases hepatic extraction of insulin. Br Med J 286:921–923,1983 · DOI
  14. Shapiro ET, Tillil H, Miller MA, Frank BH, Galloway JA, Rubenstein AH, Polonsky KS: Insulin secretion and clearance: comparison after oral and intravenous glucose. Diabetes 36:1365–1371,1987 · DOI
  15. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M: Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359:2072–2077,2002 · DOI · Paper page
  16. Herrmann C, Göke R, Richter G, Fehmann HC, Arnold R, Göke B: Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients. Digestion 56:117–126,1995 · DOI · Paper page
  17. Qualmann C, Nauck MA, Holst JJ, Ørskov C, Creutzfeldt W: Glucagon-like peptide 1 (7–36 amide) secretion in response to luminal sucrose from the upper and lower gut: a study using alpha-glucosidase inhibition (acarbose). Scand J Gastroenterol 30:892–896,1995 · DOI
  18. Knudsen LB, Pridal L: Glucagon-like peptide-1-(9–36) amide is a major metabolite of glucagon-like peptide-1-(7–36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor. Eur J Pharmacol 318:429–435,1996 · DOI
  19. Vahl TP, Paty BW, Fuller BD, Prigeon RL, D’Alessio DA: Effects of GLP-1-(7–36)NH2, GLP-1-(7–37), and GLP-1-(9–36)NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans. J Clin Endocrinol Metab 88:1772–1779,2003 · DOI
  20. Ørskov C, Jeppesen J, Madsbad S, Holst JJ: Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine. J Clin Invest 87:415–423,1991 · DOI
  21. Vilsbøll T, Krarup T, Deacon CF, Madsbad S, Holst JJ: Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 50:609–613,2001 · DOI
  22. Toft-Nielsen MB, Damholt MB, Madsbad S, Hilsted LM, Hughes TE, Michelsen BK, Holst JJ: Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 86:3717–3723,2001 · DOI · Paper page
  23. Gribble FM, Williams L, Simpson AK, Reimann F: A novel glucose-sensing mechanism contributing to glucagon-like peptide-1 secretion from the GLUTag cell line. Diabetes 52:1147–1154,2003 · DOI
  24. Nyholm B, Walker M, Gravholt CH, Shearing PA, Sturis J, Alberti KGMM, Holst JJ, Schmitz O: Twenty-four-hour insulin secretion rates, circulating concentrations of fuel substrates and gut incretin hormones in healthy offspring of type II (non-insulin-dependent) diabetic parents: evidence of several aberrations. Diabetologia 42:1314–1323,1999 · DOI
  25. Göke R, Fehmann HC, Linn T, Schmidt H, Krause M, Eng J, Göke B: Exendin-4 is a high potency agonist and truncated exendin-(9–39)-amide an antagonist at the glucagon-like peptide 1-(7–36)-amide receptor of insulin-secreting beta-cells. J Biol Chem 268:19650–19655,1993 · DOI · Paper page
  26. Thorens B, Porret A, Buhler L, Deng SP, Morel P, Widmann C: Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9–39) an antagonist of the receptor. Diabetes 42:1678–1682,1993 · DOI
  27. Kjems LL, Holst JJ, Vølund A, Madsbad S: The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. Diabetes 52:380–386,2003 · DOI · Paper page
  28. Rachman J, Gribble FM, Barrow BA, Levy JC, Buchanan KD, Turner RC: Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7–36) amide in patients with NIDDM. Diabetes 45:1524–1530,1996 · DOI
  29. Rachman J, Gribble FM, Levy JC, Turner RC: Near-normalization of diurnal glucose concentrations by continuous administration of glucagon-like peptide 1 (GLP-1) in subjects with NIDDM. Diabetologia 40:205–211,1997 · DOI
  30. Nauck MA, Weber I, Bach I, Richter S, Ørskov C, JJ H, Schmiegl W: Normalization of fasting glycaemia by intravenous GLP-1 ([7–36 amide] or [7–37]) in type 2-diabetic patients. Diabet Med 15:937–945,1998 · DOI
  31. Willms B, Idowu K, Holst JJ, Creutzfledt W, Nauck MA: Overnight GLP-1 normalizes fasting but not daytime plasma glucose values in NIDDM patients. Exp Clin Endocrinol Diabetes 106:103–107,1998 · DOI
  32. Ritzel R, Schulte M, Porksen N, Nauck MS, Holst JJ, Juhl C, Marz W, Schmitz O, Schmiegel WH, Nauck MA: Glucagon-like peptide 1 increases secretory burst mass of pulsatile insulin secretion in patients with type 2 diabetes and impaired glucose tolerance. Diabetes 50:776–784,2001 · DOI
  33. Willms B, Werner J, Holst JJ, Ørskov C, Creutzfeldt W, Nauck MA: Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7–36) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab 81:327–332,1996 · DOI · Paper page
  34. Byrne MM, Gliem K, Wank U, Arnold R, Katschinski M, Polonsky KS, Göke B: Glucagon-like peptide 1 improves the ability of the beta-cell to sense and respond to glucose in subjects with impaired glucose tolerance. Diabetes 47:1259–1265,1998 · DOI
  35. Crockett SE, Mazzaferri EL, Cataland S: Gastric inhibitory peptide (GIP) in maturity-onset diabetes mellitus. Diabetes 25:931.935,1976 · DOI
  36. Ross SA, Brown JC, Dupré J: Hypersecretion of gastric inhibitory polypeptide following oral glucose in diabetes mellitus. Diabetes 26:525–529,1977 · DOI
  37. Ebert R, Creutzfeldt W: Hypo- and hypersecretion of GIP in maturity-onset diabetics. Diabetologia 19:271–272,1980 · DOI
  38. Jones IR, Owens DR, Luzio S, Williams S, Hayes TM: The glucose dependent insulinotropic polypeptide response to oral glucose and mixed meals is increased in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 32:668–677,1989 · DOI
  39. Jorde R, Amland PF, Burhol PG, Giercksy K-E: What are “physiological” plasma levels in man after intravenous infusion of porcine GIP?Scand J Gastroenterol 20:268–271,1985 · DOI
  40. Sarson DL, Wood SM, Kansal PC, Bloom SR: Glucose-dependent insulinotropic polypeptide augmentation of insulin: physiology or pharmacology?Diabetes 33:389–393,1984 · DOI
  41. Amland PF, Jorde R, Aanderup S, Burhol PG, Giercksky K-E: Effects of intravenously infused porcine GIP on serum insulin, plasma C-peptide, and pancreatic polypeptide in non-insulin-dependent diabetes in the fasting state. Scand J Gastroenterol 20:315–320,1985 · DOI
  42. Jones IR, Owens DR, Moody AJ, Luzio SD, Morris T, Hayes TM: The effects of glucose-dependent insulinotropic polypeptide infused at physiological concentrations in normal subjects and type 2 (non-insulin-dependent) diabetic patients on glucose tolerance and B-cell secretion. Diabetologia 30:707–712,1987 · DOI
  43. Krarup T, Saurbrey N, Moody AJ, Kühl C, Madsbad S: Effect of porcine gastric inhibitory polypeptide on β-cell function in type 1 and type 2 diabetes mellitus. Metabolism 36:677–682,1987 · DOI
  44. Meier JJ, Hücking K, Holst JJ, Deacon CF, Schmiegel WH, Nauck MA: Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes. Diabetes 50:2497–2504,2001 · DOI
  45. Vilsbøll T, Krarup T, Madsbad S, Holst JJ: Defective amplification of the late phase insulin response to glucose by GIP in obese type II diabetic patients. Diabetologia 45:1111–1119,2002 · DOI · Paper page
  46. Holst JJ, Gromada J, Nauck MA: The pathogenesis of NIDDM involves a defective expression of the GIP receptor. Diabetologia 40:984–986,1997 · DOI
  47. Lynn FC, Pamir N, Ng EH, McIntosh CH, Kieffer TJ, Pederson RA: Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats. Diabetes 50:1004–1011,2001 · DOI · Paper page
  48. Chang AM, Jakobsen G, Sturis J, Smith MJ, Bloem CJ, An B, Galecki A, Halter JB: The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose. Diabetes 52:1786–1791,2003 · DOI
  49. Gromada J, Bokvist K, Ding WG, Holst JJ, Nielsen JH, Rorsman P: Glucagon-like peptide 1 (7–36) amide stimulates exocytosis in human pancreatic beta-cells by both proximal and distal regulatory steps in stimulus-secretion coupling. Diabetes 47:57–65,1998 · DOI
  50. Gromada J, Holst JJ, Rorsman P: Cellular regulation of islet hormone secretion by the incretin hormone glucagon-like peptide 1. Pflügers Arch - Eur J Physiol 435:583–594,1998 · DOI
  51. Meier JJ, Nauck MA, Siepmann N, Greulich M, Holst JJ, Deacon CF, Schmidt WE, Gallwitz B: Similar insulin secretory response to a gastric inhibitory polypeptide bolus injection at euglycemia in first-degree relatives of patients with type 2 diabetes and control subjects. Metabolism 52:1579–1585,2003 · DOI
  52. Scrocchi LA, Marshall BA, Cook SM, Brubaker PL, Drucker DJ: Identification of glucagon-like peptide 1 (GLP-1) actions essential for glucose homeostasis in mice with disruption of GLP-1 receptor signaling. Diabetes 47:632–639,1998 · DOI
  53. Pederson RA, Satkunarajah M, McIntosh CH, Scrocchi LA, Flamez D, Schuit F, Drucker DJ, Wheeler MB: Enhanced glucose-dependent insulinotropic polypeptide secretion and insulinotropic action in glucagon-like peptide 1 receptor -/- mice. Diabetes 47:1046–1052,1998 · DOI
  54. Nauck MA, Homberger E, Siegel EG, Allen RC, Eaton RP, Ebert R, Creutzfeldt W: Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 63:492–498,1986 · DOI · Paper page

Cited by

Sorted by citations

Metadata

Authors
Nauck, M. A., Baller, B., & Meier, J. J.
Affiliations
  • From the Diabeteszentrum Bad Lauterberg, Bad Lauterberg, Germany
  • Medizinische Universitätsklinik I, St. Josef-Hospital, Ruhr-Universität Bochum, Bochum, Germany
Venue
Diabetes
Publisher
American Diabetes Association
Published
2004-12-01
Volume
53
Issue
suppl_3
Pages
S190-S196
ISSN
  • 0012-1797
  • 1939-327X
DOI
10.2337/diabetes.53.suppl_3.s190
Cited by
163
References
14
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review